Stockwatch: Choppy Waters For Teva And Bausch
Could Black Swan Add To Generics Sector Woes?
Executive Summary
After most of the big pharmaceutical companies reported their full-year 2019 financial results, the second month of earnings season brings the long tail of smaller biotech companies and the generic pharmaceutical companies. There is more than one uncomfortable parallel from the former in the reports of the latter.